肥胖症药物的安全性。 - Suppr

Suppr

超能文献

The safety of obesity drugs.

作者信息

Van Gaal Luc F, Scheen André J, Formiguera Xavier

出版信息

Expert Opin Drug Saf. 2007 Sep;6(5):475-6; author reply 477-8. doi: 10.1517/14740338.6.5.475.

DOI:10.1517/14740338.6.5.475

PMID:17877434

Abstract

摘要

相似文献

The safety of obesity drugs.

Expert Opin Drug Saf. 2007 Sep;6(5):475-6; author reply 477-8. doi: 10.1517/14740338.6.5.475.

Antagonism of type-1 cannabinoid receptors: good for obesity, but is it safe for fertility?

Clin Endocrinol (Oxf). 2007 Mar;66(3):456-7. doi: 10.1111/j.1365-2265.2007.02760.x.

Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.

Obesity (Silver Spring). 2011 Jul;19(7):1325-34. doi: 10.1038/oby.2011.69. Epub 2011 Apr 7.

The psychiatric side-effects of rimonabant.

Braz J Psychiatry. 2009 Jun;31(2):145-53. doi: 10.1590/s1516-44462009000200012.

Effect of rimonabant on weight and cardiometabolic risk factors.

JAMA. 2006 Aug 9;296(6):649-50; author reply 650-1. doi: 10.1001/jama.296.6.649.

An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.

J Clin Pharm Ther. 2011 Feb;36(1):10-8. doi: 10.1111/j.1365-2710.2010.01164.x.

[Rimonabant (Acomplia)].

J Pharm Belg. 2008 Mar;63(1):27-8.

Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?

Expert Opin Pharmacother. 2005 Oct;6(12):2141-4. doi: 10.1517/14656566.6.12.2141.

Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant?

Expert Opin Investig Drugs. 2005 Mar;14(3):339-42. doi: 10.1517/13543784.14.3.339.

CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant).

J Clin Pharm Ther. 2012 Jun;37(3):260-5. doi: 10.1111/j.1365-2710.2011.01284.x. Epub 2011 Jul 11.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

The safety of obesity drugs.

Expert Opin Drug Saf. 2007 Sep;6(5):475-6; author reply 477-8. doi: 10.1517/14740338.6.5.475.

Antagonism of type-1 cannabinoid receptors: good for obesity, but is it safe for fertility?

Clin Endocrinol (Oxf). 2007 Mar;66(3):456-7. doi: 10.1111/j.1365-2265.2007.02760.x.

Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.

Obesity (Silver Spring). 2011 Jul;19(7):1325-34. doi: 10.1038/oby.2011.69. Epub 2011 Apr 7.

The psychiatric side-effects of rimonabant.

Braz J Psychiatry. 2009 Jun;31(2):145-53. doi: 10.1590/s1516-44462009000200012.

Effect of rimonabant on weight and cardiometabolic risk factors.

JAMA. 2006 Aug 9;296(6):649-50; author reply 650-1. doi: 10.1001/jama.296.6.649.

An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.

J Clin Pharm Ther. 2011 Feb;36(1):10-8. doi: 10.1111/j.1365-2710.2010.01164.x.

[Rimonabant (Acomplia)].

J Pharm Belg. 2008 Mar;63(1):27-8.

Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?

Expert Opin Pharmacother. 2005 Oct;6(12):2141-4. doi: 10.1517/14656566.6.12.2141.

Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant?

Expert Opin Investig Drugs. 2005 Mar;14(3):339-42. doi: 10.1517/13543784.14.3.339.

CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant).

J Clin Pharm Ther. 2012 Jun;37(3):260-5. doi: 10.1111/j.1365-2710.2011.01284.x. Epub 2011 Jul 11.